Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is having a great start to the trading session this morning, and for good reason. The company announced positive clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The positive clinical data;
- what we’re seeing from MRNS as a result; and
- what we’ll be watching for with regard to the stock ahead.
MRNS Is Climbing On Positive Clinical Data
As mentioned above, Marinus Pharmaceuticals is having an incredibly strong start to the trading session this morning after the company announced positive clinical data. In a press release issued early this morning, the company provided positive data from a Phase 2 clinical trial. Through the trial, MRNS is working to evaluate ganaxolone intravenous and oral in women with postpartum depression.
In the release, the company said that based on the clinical results, it is advancing both studies into the next phase of development to evaluate IV and oral dose regimens. In a statement, Dr. Lorianne Masuoka, CMO at MRNS, had the following to offer:
We achieved our Magnolia study objective and are pleased with the early onset, magnitude and durability of efficacy seen with ganaxolone IV over a month after treatment and discharge from inpatient care… Ganaxolone IV’s safety profile including ability to deliver even the highest dose at the start of infusion in these patients makes it an attractive drug candidate for this underserved patient population. The results from this Phase 2 safety and pharmacokinetic dose-optimization study are instrumental to future studies that incorporate our IV and provide insight to further optimize our oral dose regimen.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Marinus Pharmacueticals, the news proved to be overwhelmingly positive. After all, with the strong data in mind, the company is advancing the treatment in both the oral and IV doses further through the development process. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top in the market this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:05), MRNS is trading at $6.65 per share after a gain of $1.48 per share or 28.63% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on MRNS. In particular, we’re interested in following the continued development of ganaxolone as the treatment is yielding positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!